Generic Drug Labeling Rule = Product Liability Suits = Higher Prices, Study Says
This article was originally published in The Pink Sheet Daily
GPhA-sponsored economic analysis of FDA’s proposed rule estimates it will increase consumer spending on generic drugs by $4 billion annually.
You may also be interested in...
FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.
Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.
Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.